Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 416,800
  • Shares Outstanding, K 52,100
  • Annual Sales, $ 0 K
  • Annual Income, $ -160,810 K
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.34
Trade ALXO with:

Options Overview Details

View History
  • Implied Volatility 233.45% ( -34.53%)
  • Historical Volatility 105.24%
  • IV Percentile 96%
  • IV Rank 81.93%
  • IV High 283.70% on 07/03/24
  • IV Low 5.55% on 09/26/23
  • Put/Call Vol Ratio 4.73
  • Today's Volume 229
  • Volume Avg (30-Day) 267
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 11,248
  • Open Int (30-Day) 10,218

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.75
  • Number of Estimates 5
  • High Estimate -0.69
  • Low Estimate -0.84
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.29 +53.69%
on 07/05/24
8.78 -7.40%
on 07/16/24
+0.08 (+0.99%)
since 06/14/24
3-Month
5.29 +53.69%
on 07/05/24
17.83 -54.39%
on 05/07/24
-6.36 (-43.89%)
since 04/16/24
52-Week
3.94 +106.57%
on 08/31/23
17.83 -54.39%
on 05/07/24
+1.36 (+20.09%)
since 07/14/23

Most Recent Stories

More News
Why ALX Oncology Stock Is Skyrocketing Today

Investors are cheering the immuno-oncology company's latest clinical trial results.

ALXO : 8.13 (+1.63%)
Stock Index Futures Plunge Ahead of U.S. JOLTs Report, U.S. Rates Stay in Focus

December S&P 500 futures (ESZ23) are down -0.38%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.50% this morning as market participants looked ahead to the release of fresh labor market data...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NVDA : 126.36 (-1.62%)
META : 489.79 (-1.28%)
GOOGL : 183.92 (-1.40%)
PODD : 201.39 (+1.27%)
K : 57.05 (+1.30%)
TGT : 155.01 (+2.45%)
BOO.LN : 35.000 (+0.34%)
ZAL.D.DX : 24.510 (-0.08%)
ALXO : 8.13 (+1.63%)
ODD : 44.24 (+2.69%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 36.2700 (+0.86%)
GNPX : 2.0600 (+4.04%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...

ALXO : 8.13 (+1.63%)
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 8.13 (+1.63%)
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 8.13 (+1.63%)
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001...

ALXO : 8.13 (+1.63%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 9.61
2nd Resistance Point 9.20
1st Resistance Point 8.66
Last Price 8.13
1st Support Level 7.71
2nd Support Level 7.30
3rd Support Level 6.76

See More

52-Week High 17.83
Fibonacci 61.8% 12.52
Fibonacci 50% 10.88
Fibonacci 38.2% 9.24
Last Price 8.13
52-Week Low 3.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar